Affymax (OTCMKTS:AFFY) and Assembly Biosciences (NASDAQ:ASMB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.
This table compares Affymax and Assembly Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Affymax has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.
This is a breakdown of current recommendations for Affymax and Assembly Biosciences, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Assembly Biosciences has a consensus price target of $41.33, indicating a potential upside of 157.37%. Given Assembly Biosciences’ higher probable upside, analysts clearly believe Assembly Biosciences is more favorable than Affymax.
Insider and Institutional Ownership
79.6% of Assembly Biosciences shares are owned by institutional investors. 1.6% of Affymax shares are owned by company insiders. Comparatively, 12.4% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Affymax and Assembly Biosciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Assembly Biosciences||$14.80 million||28.26||-$90.75 million||($3.98)||-4.04|
Affymax has higher earnings, but lower revenue than Assembly Biosciences.
Assembly Biosciences beats Affymax on 5 of the 9 factors compared between the two stocks.
Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.
About Assembly Biosciences
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in two Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in investigational new drug-enabling studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, and immuno-oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.
Receive News & Ratings for Affymax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymax and related companies with MarketBeat.com's FREE daily email newsletter.